Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Alkannin Attenuates Amyloid β Aggregation and Alzheimer’s Disease Pathology

Toru Hosoi, Kyosuke Yazawa, Michihiro Imada, Akari Tawara, Chihiro Tohda, Yasuyuki Nomura and Koichiro Ozawa
Molecular Pharmacology May 2023, 103 (5) 266-273; DOI: https://doi.org/10.1124/molpharm.121.000468
Toru Hosoi
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyosuke Yazawa
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michihiro Imada
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akari Tawara
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chihiro Tohda
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuyuki Nomura
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichiro Ozawa
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 103 no. 5 266-273
DOI 
https://doi.org/10.1124/molpharm.121.000468
PubMed 
36868792

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0026-895X
Online ISSN 
1521-0111
History 
  • Received December 1, 2021
  • Accepted January 4, 2023
  • Published online April 13, 2023.

Article Versions

  • Earlier version (March 3, 2023 - 12:47).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Toru Hosoi1,
  2. Kyosuke Yazawa1,
  3. Michihiro Imada,
  4. Akari Tawara,
  5. Chihiro Tohda,
  6. Yasuyuki Nomura, and
  7. Koichiro Ozawa
  1. Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Sanyo Onoda, Japan (T.H.); Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, Minami-ku, Japan (K.Y., M.I., A.T., K.O.); Department of Pharmacology, Kurume University School of Medicine, Kurume, Japan (Y.N.); and Section of Neuromedical Science, Division of Bioscience, Institute of Natural Medicine, University of Toyama, Toyama, Japan (C.T.)
  1. Address correspondence to:
    Toru Hosoi, Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, 1-1-1 Daigaku-dori, Sanyo Onoda City, Yamaguchi 756-0884, Japan. E-mail: hosoi{at}rs.socu.ac.jp: or Koichiro Ozawa, Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan. E-mail: ozawak{at}hiroshima-u.ac.jp
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: March 2023 to June 2023

AbstractFullPdf
Mar 2023302025
Apr 20234562122
May 20232482619
Jun 20235142

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 103 (5)
Molecular Pharmacology
Vol. 103, Issue 5
1 May 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Alkannin Attenuates Amyloid β Aggregation and Alzheimer’s Disease Pathology
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Alkannin Attenuates Amyloid β Aggregation

Toru Hosoi, Kyosuke Yazawa, Michihiro Imada, Akari Tawara, Chihiro Tohda, Yasuyuki Nomura and Koichiro Ozawa
Molecular Pharmacology May 1, 2023, 103 (5) 266-273; DOI: https://doi.org/10.1124/molpharm.121.000468

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Alkannin Attenuates Amyloid β Aggregation

Toru Hosoi, Kyosuke Yazawa, Michihiro Imada, Akari Tawara, Chihiro Tohda, Yasuyuki Nomura and Koichiro Ozawa
Molecular Pharmacology May 1, 2023, 103 (5) 266-273; DOI: https://doi.org/10.1124/molpharm.121.000468
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Action of Org 34167 on HCN channels
  • The effects of echinocystic acid on Kv7 channels
  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics